claim: two trial of gilead's potential coronavirus treatment suspended
evidence_1: [nl3n2by1ah] the study was conducted by researchers in china and the suspension was posted bit.ly/3bcnyv4 on wednesday on clinicaltrials.gov, a database maintained by the u.s. national institutes of health (nih).", "reuters/stephen lam gilead shares, which have risen nearly 20% in year through tuesdays close, were down 3% at $75.27 earlier, another trial in china testing the drug in those with severe covid-19 was terminated because no eligible patients could be enrolled.")